Evaluating cardiac lead safety using observational, real-world data: EP PASSION proof-of-concept study
Heart Rhythm · 2025
DOI: 10.1016/j.hrthm.2024.06.045 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift Heart Rhythm, 2025. Verfasst von Lorenzo Braghieri und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, Cleveland Clinic, Cleveland, Ohio. Hauptthemen laut MEDLINE: Defibrillators, Implantable, Product Surveillance, Postmarketing, Pacemaker, Artificial. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 19 Literaturangaben. Gefördert von: Centre on Innovation and Energy Demand, University of Sussex, Abbott Laboratories.
Abstract (Originalsprache)
BACKGROUND: Traditional post-approval study (PAS) designs have been accepted by regulatory authorities to fulfill postmarketing requirements for cardiac leads, but they have several limitations. OBJECTIVE: We conducted a proof-of-concept study of alternative methods that use real-world data (RWD) to evaluate lead safety in large populations of patients. METHODS: Abbott patient device databases were linked with Medicare Fee-For-Service (FFS) claims to identify lead complications in patients implanted with Abbott Optisure lead. A 1:1 comparison between the PAS method and RWD method of detecting mechanical lead-related complication events was conducted in 444 PAS participants who were enrolled in Medicare FFS. Agreement between methods was evaluated by McNemar test and Cohen κ. Survival free from complications at 3 years was compared between the PAS and RWD cohorts with an equivalence acceptance criterion of ±2.5%. RESULTS: There were 1171 PAS patients and 5804 Medicare FFS patients who received an Optisure lead between August 27, 2014, and June 14, 2016. Patients were observed through December 31, 2018. Complete agreement was found between PAS-reported and claims-detected complications (McNemar P value = 1; Cohen κ = 1). Survival free from complications at 3 years by the RWD method was 98.4% (95% confidence limit, 98.0%-98.7%), which was within the acceptable range of the PAS 98.4% (95% confidence limit, 97.6%-99.0%). CONCLUSION: These results show a close agreement between RWD-detected and PAS-reported lead complication rates, which highlights the potential benefits of RWD-based methods to enhance the generation of clinical evidence for lead safety.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Internal Medicine, Cleveland Clinic, Cleveland, Ohio.
- Department of Medicine, Jacobs School of Medicine and Biomedical Sciences, University at Buffalo, Buffalo, New York. Electronic address: aamirahm@buffalo.edu.
- Department of Medicine, Jacobs School of Medicine and Biomedical Sciences, University at Buffalo, Buffalo, New York.
- Abbott Laboratories, Sylmar, California.
- Cleveland Clinic Heart, Thoracic, and Vascular Institute, Cleveland, Ohio.
Förderung
- Centre on Innovation and Energy Demand, University of Sussex
- Abbott Laboratories
Zitieren
APA
Braghieri, L., Ahmed, A., Curtis, A. B., Kim, J. A., Connolly, A. T., Nabutovsky, Y., Kim, G., Ganz, L., & Wilkoff, B. L. (2025). Evaluating cardiac lead safety using observational, real-world data: EP PASSION proof-of-concept study. Heart Rhythm. https://doi.org/10.1016/j.hrthm.2024.06.045
Vancouver
Braghieri L, Ahmed A, Curtis AB, Kim JA, Connolly AT, Nabutovsky Y, et al. Evaluating cardiac lead safety using observational, real-world data: EP PASSION proof-of-concept study. Heart Rhythm. 2025. doi:10.1016/j.hrthm.2024.06.045
BibTeX
@article{Braghieri2025,
author = {Braghieri, Lorenzo and Ahmed, Aamir and Curtis, Anne B and Kim, Jeeyun A and Connolly, Allison T and Nabutovsky, Yelena and Kim, Grant and Ganz, Leonard and Wilkoff, Bruce L},
title = {Evaluating cardiac lead safety using observational, real-world data: EP PASSION proof-of-concept study},
journal = {Heart Rhythm},
year = {2025},
doi = {10.1016/j.hrthm.2024.06.045}
}
EUVIMED